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Fibroblast growth factors were first characterized twenty years ago as
mitogens of cultured fibroblasts. Despite a wealth of data from experiments
in vitro, insights have begun to emerge only recently on the normal
function of these growth factors in mice and humans, as a result of studies
of natural and experimental mutations in the factors and their receptors.
The FGF family of ligands
The fibroblast growth factor (FGF) family has grown
since the first characterization of FGF as a fibroblast
mitogen [1], to a current membership of nine, FFs
1-9. High resolution X-ray structures of crystals of both
FGF-1 and FGF-2 have been reported; these reveal a 'P3
trefoil' topology, comprising 12 strands linked to form a
three-fold symmetrical structure [2]. On the basis of se-
quence conservation, it seems very likely that all mem-
bers of the FGF family have related three-dimensional
structures. At least some members of the family are also
highly conserved in vertebrate evolution: amphibian
homologues of FGF-2, FGF-3 and FGF-4 have been
described [3-5]. There are now good descriptive data
available on the expression of most FGF family members
in the mouse (for example, see [6,7]), and less extensive,
although generally corroborative, data for other species.
Taken together, this evidence reveals two features of
the developmental gene expression of the FGF family:
firstly, each member exhibits a characteristic pattern of
expression, and secondly, viewed as a whole, the FGFs
are expressed at many stages and places in the both the
developing and the mature organism.
The biological effects of the FGFs are mediated by asso-
ciation with three biochemically distinct partners: hepa-
ran sulphate oligosaccharides [8,9], a low-affinity trans-
membrane FGF-binding protein [10], and high-affinity
transmembrane FGF receptors of the tyrosine kinase
class. Transfection and reconstitution experiments (for ex-
ample [11,12]) have shown that intracellular signal trans-
duction is triggered by activation of FGF receptor tyro-
sine kinase activity. Activation is brought about by
receptor oligomerization, which is mediated by the asso-
ciation of heparin with the ligand (FGF) [13] and of the
ligand with the receptor; it is also possible that heparin
associates with the receptor itself [14]. The role of the
low-affinity transmembrane FGF-binding protein is at
present obscure, although sequence considerations [10]
suggest that it is more likely to play a role in the cellular
uptake of FGF than to participate directly in pathways
that transduce the FGF signal.
The transmembrane tyrosine kinase class of FGF re-
ceptors, as the main agents of signal transduction, are
clearly essential for the biological function of FGFs. Four
unlinked genes that encode FGF receptors, FGFR1-
FGFR4, are currently known; the amino-acid sequences
encoded by these four genes have related features (re-
viewed in [15]). The cytoplasmic region is principally
composed of the tyrosine kinase domain, and it contains a
number of consensus tyrosine residues that could act as
phosphate acceptors for autophosphorylation. Most, but
not all, of these residues are conserved amongst the FGF
receptor family.
The receptor extracellular region comprises three do-
mains, IgI-IgIII, each of which exhibits clear hallmarks
of the immunoglobulin superfamily of structural modules
(reviewed in [16]). IgI and IgII are separated by a se-
quence that is rich in acidic amino acids (the 'acid box')
and appears essential for receptor function [17]. The
interaction of ligand with the extracellular region of the
receptor is, however, mediated by sequences present in
both IgII and IgIII domains [18-20]. An important fea-
ture of the IgIllI domain in the FGFR1-FGFR3 proteins
is that it is encoded by three exons and produced by
alternative splicing of a common 5' exon, IgIIa, onto
either an IgIIIb or an IgIIIc variant exon. The signifi-
cance of this alternative splicing in the IgIIl domain is
that it dictates ligand specificity. In the case of FGFR1
and FGFR2, the IgIIIa/IgIIIb form of the receptor binds
to FGF-7 with high affinity, whereas the IgIIIa/IgIIIc
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form binds other members of the FGF family with high
affinity [21,22]. In the case of FGFR3, the IgIIIa/IgIIIb
variant preferentially binds to FGF-1, whereas the alter-
native variant IgIIIa/IgIIc displays much broader bind-
ing specificity [23]. Although the description of FGFR
expression (and splice variants) in development is by no
means complete, there is enough evidence to suggest that
each receptor isoform exhibits a characteristic pattern of
expression in both embryonic and adult life, and many
tissues and cells express a 'repertoire' of multiple FGF
receptor genes and splice variants [24].
Animal models of FGF function
Clearly, FGF biology is potentially very complex, involv-
ing multiple ligands, receptors and cofactors, each ex-
pressed with different spatial and temporal patterns and
distinct kinetics in the course of normal development.
Considerable effort has been expended on the creation of
different types of animal model for the analysis of FGF
function in vivo. These studies clearly indicate that FGF
signalling is involved in a number of different processes at
different stages of development.
Homozygous null mutations
Gene ablation by homologous recombination is regarded
as a highly informative test of gene function. The con-
sequences of genetic inactivation of both FGF ligands
and FGF receptors are now beginning to be revealed (see
Table 1). Although the effects of inactivation need to be
examined for the complete set of ligands, receptors and
cofactors, both alone and in combination, some prelimi-
nary conclusions can be drawn.
Firstly, it is instructive that inactivation of individual FGF
ligands leads to quite distinct effects, ranging from peri-
implantation lethality [25] to minor disturbances in hair
development [26]. These data show that different FGF
family members have discrete biological functions. The
second conclusion is that FGF signalling is critical at very
early developmental stages: homozygous FGF-4 and
FGFR1 null mutations both cause early lethality. The
fact that FGF-4-null mice [25] die earlier than FGFR1-
null mice [27,28] indicates that one (or more) other
member(s) of the FGF receptor family is also critical for
early embryonic development. Although this finding
clearly establishes the importance of FGF signalling in
early development, it also precludes the use of gene
ablation for the analysis of FGF-dependent pathways in
later development and adulthood.
Dominant-negative receptors
An alternative approach to the analysis of FGF receptor
action, which has some advantages over gene ablation for
the dissection of function, is the use of dominant-nega-
tive FGFR mutants. These encode mutant receptors with
truncated cytoplasmic domains, which inhibit the signal-
ling mediated by resident wild-type receptors by forming
inactive heterodimers in the presence of ligand [29].
Dominant-negative FGF receptors have been used with
some success in the analysis of amphibian early develop-
ment [30]. A potentially useful feature of dominant-nega-
tive receptors is that, because their activity depends upon
interaction with the ligand, their action specifically reveals
aspects of receptor function that require both activation
of intracellular signalling and interaction with the ligand.
Two studies have been reported in which dominant-nega-
tive FGF receptors expressed under the control of strong
tissue-specific promoters in transgenic mice have been
used to investigate FGF function in later development. In
one case, the human surfactant protein C promoter was
used to target expression of a dominant-negative FGFR2
(IgIIIb variant) exclusively to lung-bud epithelium in
transgenic mice [31]. This resulted in lethality: newborn
mice expressing the transgene had, in place of lungs, two
undifferentiated and unbranched epithelial tubes that
extended from the bifurcation of the trachea down to the
diaphragm. In the second case [32], a dominant-negative
FGFR2 (IgIIIb variant) construct was targeted to supra-
basal keratinocytes using a keratin 10 promoter. Expres-
sion of the mutant receptor disrupted the organization of
epidermal keratinocytes, induced epidermal thickening
and resulted in aberrant expression of keratin 6. These
findings reveal that FGF signalling is required for both
branching morphogenesis of the lung and the establish-
ment of the normal program of keratinocyte differentia-
tion in the skin. It seems very likely that these are just
two examples of a diversity of FGF signalling functions in
morphogenesis and differentiation.
Targeted overexpression
A complementary approach to analyzing FGF function is
to examine the consequences of activating FGF signal-
ling. This is usually achieved by ectopic application or
expression of FGF ligands and reveals FGF-dependent
signalling pathways that are controlled by the availability
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of ligand. The strategy has been used to most effect in
the analysis of limb development. In particular, FGF sig-
nalling has been shown to be involved in both the initial
induction and sustained outgrowth of the limb bud dur-
ing early limb development [33]. Perhaps the most dra-
matic illustration of this function of FGF signalling is the
ability to induce supernumerary limb development in the
chick by local application of an FGF-soaked bead [34].
These findings show that FGF has a major role in both
specification and development of the limb, and that at
least some FGF-dependent processes are regulated by
accessibility of an FGF ligand.
FGF receptor mutations in human genetic disease
In the light of the evidence from animal models, it is
clear that either ablation or activation of FGF signalling
can have major harmful effects in embryonic develop-
ment. It would therefore seem unlikely that alteration of
FGF receptor function could lead to a viable adult phe-
notype. It is of considerable interest therefore that muta-
tions in FGF receptor genes have, in the last year, been
identified as the underlying causes of several human dis-
orders of bone growth and patterning. The initial clue to
these discoveries came from genetic linkage analysis in
three human disorders: Pfeiffer syndrome, Crouzon syn-
drome and achondroplasia. These were localized to chro-
mosomes 8p, 10q and 4p, respectively. The FGFR genes
1, 2 and 3 had previously been mapped to these regions
by physical methods, and subsequent searches for muta-
tions in these genes [35-38] in affected individuals have
dramatically borne fruit.
The first gene to yield mutations was FGFR3. An identi-
cal heterozygous Gly-Arg substitution in the transmem-
brane domain of FGFR3 was identified in all 39 patients
examined with achondroplasia [37,38]. A heterozygous
Gly-4Cys substitution located five residues away in the
same domain has also been reported recently [39]. Achon-
droplasia is the most common genetic form of dwarfism,
and is characterized by disproportionate shortening of the
long bones of the limbs due to failure of cell proliferation
at the epiphyseal plates during skeletogenesis. Homo-
zygotes are very severely affected and usually die before, or
shortly after, birth. A potential explanation of the effects
of this mutation is the ligand-independent activation of
receptor signalling as a result of dimerization of the mu-
tant receptors, mediated by the mutant transmembrane
domain. An analogous mechanism of receptor activation
has been advanced in the case of the Her-2 receptor [40].
The hallmark of both Pfeiffer and Crouzon syndromes is
craniosynostosis, an abnormality of the developing skull
in which the sutures between the growing bones fail to
form or fuse prematurely (Fig. la). This leads to distor-
tions in the shape of the skull, sometimes associated with
bulging eyes, enlarged cerebral ventricles and breathing
problems. Although the facial features of Pfeiffer and
Crouzon syndromes are quite similar, they can be differ-
entiated by the pattern of limb involvement. Crouzon
patients have normal hands and feet, whereas in Pfeiffer
syndrome the thumbs and big toes are broad, and mild
webbing between the digits may occur. Analysis of five
families with Pfeiffer syndrome revealed a specific Pro--)
Arg substitution in the IgIIIa exon of FGFR1 [35]. Fur-
ther studies of FGFR mutations in Pfeiffer patients have
uncovered a second class of mutation, in the IgIlIc exon
of FGFR2 [41,42]. In 13 published and 10 unpublished
cases of Crouzon syndrome, a variety of mutations has
been revealed in the IgIlla and IgIIIc exons of FGFR2,
including some at identical residues to those identified in
Pfeiffer syndrome (Table 2).
More recently, two further craniosynostosis syndromes
have been associated with FGFR2 mutations. Apert syn-
drome is characterized not only by craniosynostosis but
also by severe bony syndactyly of the hands and feet (Fig.
lb). A series of 40 Apert patients were identified as har-
bouring mutations in the IgIIa exon of FGFR2 [43].
Finally, Jackson-Weiss syndrome is a rare condition, de-
scribed in a large Amish pedigree, which involves cranio-
synostosis in association with fusion between the bones
of the feet. This family has a specific mutation in the
IgIIc exon of FGFR2 [44].
Our current understanding of the spectrum of human
mutations in FGF receptor genes is summarized in Fig-
ure 2. Viewed together, the four craniosynostosis syn-
dromes that are associated with mutations in FGFRI and
Fig. 1. (a) Crouzon syndrome. The tall
forehead and anterio-posterior flatten-
ing of the skull profile are due to pre-
mature fusion of the coronal (transverse)
cranial suture. (b) Apert syndrome. The
three central digits of the hands show
severe syndactyly, with a single trans-
verse nail and underlying bony fusion of
the phalanges.
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FGFR2 exhibit some important similarities. Firstly, all
are manifest in individuals heterozygous for the mutation;
the mutant alleles therefore exhibit dominance. The phe-
notype of homozygous mutant individuals is unknown,
but homozygosity may well be lethal. Secondly, all four
syndromes involve the common feature of craniosynosto-
sis, but with variable involvement and severity of syn-
dactyly in the hands and feet. Thirdly, all the mutations
map to two specific regions of FGFR1 and FGFR2: the
IgIIIa and IIIc exons and a specific Ser-Pro motif found
at the 5' end of the IgIIIa exon. The discovery of this set
of human FGFR mutations, each of which has signifi-
cant, but non-lethal, biological consequences, has impor-
tant implications for understanding FGF receptor design
and function.
Implications for FGF receptor function
On the basis of information gleaned from the animal
models of FGF dysfunction described above, it seems un-
likely that the human mutations simply involve loss of re-
ceptor function; there have been no reports, for example,
of craniosynostosis in FGFR 1- /+ heterozygous animals. It
seems equally unlikely that the mutations involve gain-
of function dominant-negative receptor mutations; these
are usually associated with mutations in the cytoplasmic
domain of a receptor which affect signal transduction.
A complete understanding of the function of craniosyn-
ostosis-associated mutations requires knowledge of the
three dimensional structure of FGF receptors, and this
information is currently lacking. A provisional model of
FGF receptor structure can, however, be built on the basis
of known structures of members of the immunoglobulin
Fig. 2. Mutations of three FGF receptor
genes in five human disorders. The por-
tion of each FGFR that is shown com-
prises Igilla and Igillc, flanked by parts
of Igll and the transmembrane domain.
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Fig. 3. Crystal structure of FGF and
homology model of FGF receptor
domains IgIl and Igill. The crystal struc-
ture of FGF-2 is that of Zhu et al. [2]. By
sequence analysis, the IgIl and Iglll
domains of the FGF receptor are pre-
dicted to conform to the topology of
I-set immunoglobulin domains ([53] and
C. Chothia, personal communication),
represented here by the crystal structure
of telokin. The inter-domain linker
sequence shows sequence similarity to
that of the VCAM domain 1-2 linker.
The linker and relative domain orienta-
tion is therefore modelled on the crystal
structure of VCAMdl,2 [541. Residues
predicted to be encoded by the variant
exons Illb and Illc are coloured in yel-
low and include the DE loop, which
represents a major insertion in the FGF
receptor compared to known structures:
the current model merely indicates the
relative size of such a loop. The remain-
der of the molecule is shown in pink,
and the serine, proline and cysteine
residues discussed in the text are shown
in green Modelling was carried out
using the graphics package FRODO[55]. The orientation of FGF-2 is based
upon the identification of residues
involved in receptor binding [561.
superfamily. Such a model for the pair of immunoglobu-
lin domains implicated in ligand binding, IgII and IgIII, is
presented in Figure 3. On the basis of this model, the two
principal target regions for mutation in craniosynostosis-
associated syndromes lie in quite distinct locations in the
three-dimensional structure and have, despite the overall
similarity in phenotype, somewhat different implications
for the mechanism of mutant receptor action.
A notable feature of many IgII mutations is the loss or
creation of cysteine residues. A buried pair of disulphide-
bonded cysteines is a frequent (but not ubiquitous) fea-
ture of immunoglobulin superfamily members [16]. Two
of the target residues, Cys 278 and Cys 342, are pre-
dicted to be involved in this canonical bond. These two
residues are conserved throughout the FGF receptor fa-
mily, suggesting that they are important for structural sta-
bility. Indeed, mutations in the equivalent residues of
FGFR1 have been shown to abolish ligand binding [20].
Mutation of one partner in the bond would have two
consequences: first, the possibility of local unfolding of
the IgII domain (especially in the case of mutation to a
polar amino acid), and second, the creation of a free, un-
paired cysteine residue. The significance of unbonded
cysteine is also suggested by the existence of other IgII
mutants in which residues, predicted by model building
to be exposed, are mutated to cysteine. It is notable that
mutations at other sites in the IgIIl domain (such as
Tyr 340) either involve residues that are both highly con-
served amongst all FGFRs and predicted to play a key
structural role in the immunoglobulin fold, or introduce
proline residues that may inhibit correct folding. It is con-
ceivable that these mutations not only disrupt the tertiary
structure of IgIII but also destabilize the disulphide bond
that is predictedto exist between Cys 278 and Cys 342.
The creation of free, exposed cysteine residues as a
direct, or indirect, consequence of mutation suggests a
possible mechanism for the dominant phenotypic effects
of IgIII mutations: FGF receptor dimerization by inter-
molecular disulphide bonding leading to ligand-inde-
pendent activation. There are precedents for this mech-
anism of activation in both the erythropoietin and the
epidermal growth factor (EGF) receptors, in each of
which ligand-independent activating mutations have
been created by introduction of a free cysteine [45,46].
In addition, MEN-2A mutations of the RET gene in-
volve point mutation of cysteine residues in the extracel-
lular domain of the encoded protein and result in onco-
genic activation [47]. Ligand-mediated receptor activation
by intermolecular disulphide bonding has also been
invoked in the action of interleukin 6 [48]. This analysis
would lead to the proposal that craniosynostosis-associ-
ated IgII mutations lead to ligand-independent receptor
signalling. It is also conceivable that intermolecular di-
sulphide bonding between mutant receptors and the free
exposed cysteine residues in the FGF ligand leads to
inappropriate receptor oligomerization.
The second target site for FGFR mutation is a pair of
residues encoded by the 5' end of the IgIIa exon: Ser 252
and Pro 253 (FGFR2 numbering). This pair of residues is
highly conserved in the FGFR family and has been found
to be mutated in both FGFR2 and (at the corresponding
proline residue) FGFR1. Modelling studies (Fig. 3) sug-
gest that these residues are located in a short linker that
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Fig. 4. Normal tissue organization sites that are affected by FGF receptor mutations.
connects the IgII and IgIII domains. It is not immediately
obvious why mutations in this region should have biolo-
gical consequences, but the fact that mutations in this re-
gion and in exon IgIIIc (discussed above) both result in
craniosynostosis suggests that a similar functional distur-
bance is induced by two different strategies. This could,
in particular, include changes to the inter-domain confor-
mation which mimic or accentuate the effects of ligand
binding. The significance of inter-domain orientation for
ligand engagement has recently been highlighted in stud-
ies that compare the interaction of growth hormone with
either the growth hormone receptor [49] or the prolactin
receptor [50]. The identification of mutations in the inter-
domain region of the FGF receptor may have important
consequences for understanding the mechanism of inter-
action between the FGF ligand and wild-type receptor.
Structural and genetic considerations, therefore, point to
the possibility that craniosynostosis mutations involve
activation of FGF receptor signalling. This possibility is
consistent with an additional piece of evidence. The Bulgy
eye mutation in the mouse results from a retroviral in-
sertion event between the genes encoding FGF-3 and
FGF-4 (M. Carlton and M. Evans, personal communica-
tion). The phenotype of Bulgy eye mice is strongly remi-
niscent of human craniosynostosis syndromes, and it is
tempting to suggest that it arises as a result of ectopic
activation of FGF receptor signalling mediated by FGF-3
or FGF-4.
Biological specificity
A provisional explanation for the phenotype of human
FGFR mutations is, therefore, that they represent a vari-
ety of different schemes for activating receptor signalling.
This explanation would lead to the prediction that the
biological consequences result from an excess of FGF-
mediated functions. The currently available embryological
data suggest that major and deleterious consequences
would arise in embryonic life from widespread activation
of FGF receptor signalling. The many precedents of acti-
vating mutations in intrinsic tyrosine-kinase receptors
would also suggest a predisposition to tumourigenesis
in patients with FGFR mutations, which has not been
detected. This analysis, therefore, fails to explain the bio-
logical basis or specificity of the craniosynostosis or
achondroplastic FGFR mutations.
The growth of skeletal elements, and their maintenance
as discrete individual structures separate from adjacent
elements, depends upon a balance between cell prolifera-
tion and differentiation. Cell proliferation occurs at spe-
cific sites within the developing skeleton, such as the
epiphyseal plates of long bones and the sutures of the
skull. These sites are eventually lost to ossification at pre-
cise stages of postnatal life as the epiphyses and sutures
fuse (Fig. 4). The separation of adjacent skeletal elements
in the hand or foot may be analogous, being character-
ized by the presence of undifferentiated proliferating me-
senchyme between the nascent metacarpals or metatarsals
and the proximal parts of the digits. In the hand and foot,
however, the developmental fate of interskeletal mesen-
chyme is partly apoptosis but mainly the formation of con-
nective tissue, which maintains a permanent separation of
the skeletal elements. In the case of Apert syndrome, the
failure of skeletal elements to be maintained as separate
structures continues into adult life, with progressive ske-
letal fusions. Analysis of existing syndactylous mouse
mutants, such as Oligosyndactylism [51], suggests that defi-
ciency of interdigital mesenchyme from an early stage
leads to premature fusion of adjacent areas of condensing
precartilaginous mesenchyme.
Achondroplasia, craniosynostosis and syndactyly therefore
appear to result from failure or insufficiency of specific
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areas of interskeletal tissue in the execution of proliferative
(or anti-differentiative) functions. The molecular func-
tions of mutant FGF receptors must accordingly be un-
derstood in this light. The specificity of the phenotypes
arising from FGFR mutation also requires that the regula-
tion of interskeletal tissue function by FGFs exhibits some
special, and hitherto unexpected, biological properties.
The new findings from clinical molecular genetics have
therefore raised important issues for both FGF receptor
function and skeletal biology. The challenge now is to
complete the connections between knowledge of altered
genotype and the molecular basis of altered phenotype.
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